Tree pollen allergy immunotherapy - Lofarma

Drug Profile

Tree pollen allergy immunotherapy - Lofarma

Alternative Names: Carbamylated monomeric tree pollen drops; LAIS Birch-Alder tablets; Lais Frühblüher sublingual drops; Tree-pollen allergoid - Lofarma

Latest Information Update: 18 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lofarma S.p.A
  • Class Allergens; Antiallergics; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic rhinoconjunctivitis

Most Recent Events

  • 11 Dec 2017 Phase-II clinical trials in Allergic rhinoconjunctivitis in Germany (Sublingual) (EudraCT2017-003063-34)
  • 09 Dec 2013 Phase-III clinical trials in Allergic rhinoconjunctivitis (prevention, in adults and elderly) in Germany (Sublingual) (EudraCT2013-002129-43)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top